![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
FDA Approves First ALS Treatment Via Accelerated Approval
WEBApr 25, 2023 · ALS Association Funded Antisense Technology Behind Tofersen. Washington, D.C. (April 25. 2023) – The ALS Association commends the FDA for approving tofersen under the agency’s accelerated approval pathway for the treatment of people living with ALS connected to mutations in the SOD1 gene.
ALS News Today Home | ALS News Today
WEBTargeting 3 cell types at same time seen to extend survival in ALS mice. A strategy that simultaneously targets motor neurons, astrocytes, and microglia — three cell types involved in the development and progression of amyotrophic lateral sclerosis (ALS) — was shown to further extend survival in a mouse model of the disease.
Amyotrophic Lateral Sclerosis News -- ScienceDaily
WEBMar 13, 2024 · Latest research news on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, including experimental treatments.
A “Game-Changer” – Groundbreaking Discovery Paves Way for ALS …
WEBMay 29, 2024 · In a groundbreaking Canadian discovery powered by philanthropy, a team of Western University researchers led by Dr. Michael Strong has uncovered a potential path toward a cure for amyotrophic lateral sclerosis (ALS).
Phase 1 clinical trial of experimental ALS therapy ... - ALS News …
WEBAug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).
Steep Decline Of ALS Patients Slowed Via A New Drug Combo : Shots ... - NPR
WEBSep 2, 2020 · Scientists say new drugs are on the way for patients with ALS. The latest is a two-drug combo that appears to slow the progression of the fatal nerve disease with a modest but meaningful benefit.
FDA final approval decision on NurOwn for ALS due by year’s end
WEBJun 8, 2023 · A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now expected no later than Dec. 8.
New Treatment Strategy Offers Hope for Halting ALS Progression
WEBJan 30, 2024 · A major breakthrough in the treatment of amyotrophic lateral sclerosis, known as ALS, can potentially help stop the disease in its tracks in as much as half of the cases in the U.S., a Northeastern University scientist says.
In reversal, FDA panel votes to recommend experimental ALS drug - NBC News
WEBSep 7, 2022 · A Food and Drug Administration advisory panel voted Wednesday to recommend an experimental drug for patients with ALS, a reversal from its decision in March and a victory for advocacy groups ...
ALS neuron damage reversed with new compound
WEBFeb 23, 2021 · Northwestern University scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims.